#United States #San Diego #Crenessity #Neurocrine Biosciences #INGREZZA

Neurocrine Biosciences Reports Financial Results for 2025

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has recently disclosed its financial performance for the fourth quarter and full year of 2025, showcasing a remarkable trajectory in both net product sales and overall growth metrics. The company recognized fourth-quarter net product sales totaling $798.3 million, contributing to a significant full-year total of $2.83 billion. This indicated a year-over-year increase of 29% for the fourth quarter and 22% for the entire year, underlining the stability and growth potential of its commercial operations.

Highlights from the Report

In the recent financial announcement, Kyle W. Gano, Ph.D., the CEO of Neurocrine Biosciences, emphasized the company’s transition into a more diversified biopharmaceutical entity, aimed at ensuring sustainable growth. He stated, “Our performance reflects the strength of our commercial business while marking our progress toward a comprehensive suite of treatment options.”

2025 Growth Overview

Neurocrine's flagship product, INGREZZA (valbenazine), generated an impressive $657.5 million in the fourth quarter and a total of $2.51 billion for the year. This success was largely driven by strong prescription volume growth, despite facing pricing pressures due to investments aimed at expanding access and supporting long-term growth strategies.

Conversely, CRENESSITY (crinecerfont) also had a strong showing with $135.3 million in net product sales during Q4 and $301.2 million for the total year. The significant growth in new patient enrollments signals robust demand and a clear market position, especially with over 80% reimbursement coverage reported in the last quarter.

Key Developments in Clinical Research

The company did not just stop at sales figures; it made strides in its clinical pipeline as well. A notable publication highlighted the unique profile of INGREZZA compared to its counterparts, emphasizing its selective VMAT2 targeting and ease of dosing. This knowledge adds to the confidence in Neurocrine's products as they strategize their next moves in the market.

Additionally, Neurocrine showcased robust clinical efficacy through multiple presentations, including a compelling head-to-head trial demonstrating INGREZZA’s superior performance relative to AUSTEDO XR.

The company is steering efforts towards its clinical programs, notably pushing forward with Phase 3 trials for significant candidates like osavampator in treating major depressive disorder and direclidine for schizophrenia, presenting a strong case for future enhancement of their product offerings.

Financial Forecast for 2026

Looking ahead, Neurocrine has set ambitious expectations for 2026. The company targets net product sales for INGREZZA to be between $2.7 billion and $2.8 billion, indicating a sustained commitment to clinically impactful growth. In conjunction with sales forecasts, it anticipates the GAAP R&D expenses to reach approximately $1,200 million to $1,250 million, demonstrating their investment in innovation.

Conclusion

Neurocrine Biosciences has vented remarkable growth and a clear strategic focus that could elevate its market position substantially in the coming years. The solid financial performance in 2025, along with their future growth estimates and strategic developments in clinical research, seem to create a hopeful outlook for stakeholders and patients alike. The potential enhancements to Neurocrine's portfolio of therapeutic options signify not just organizational ambition but a genuine dedication to addressing pressing medical needs in neuropsychiatric care and beyond.